Optimi Health Completes Psilocybin Production Batch


Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Optimi Health Completes Psilocybin Production for Phase 2 Trial and Commercial Supply
VANCOUVER, British Columbia, Canada -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, has announced the completion and quality release of a production batch of 5mg naturally derived psilocybin capsules. Manufactured end to end at the company cGMP facility in Princeton, British Columbia, under a Health Canada Drug Establishment Licence, the batch will supply both an upcoming clinical trial and commercial customers.
... Read on — Members only




















